SLG
DGX icon

Stanley-Laman Group’s Quest Diagnostics DGX Stock Holding History

Stanley-Laman Group’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,398
Closed -$251K – 274
2025
Q2 		$251K Buy
1,398
+190
+16% +$33K 0.04% 259
2025
Q1 		$204K Buy
+1,208
New +$198K 0.03% 271

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Stanley-Laman Group's DGX Position: Q3 2025 in Review

Stanley-Laman Group sold out of Quest Diagnostics (DGX) in Q3 2025, closing a stake of 1,398 shares — an estimated $251K sold.

Stanley-Laman Group first reported a position in DGX in Q1 2025 and held it in 2 quarters. The position peaked at $251K in Q2 2025. 1,005 funds tracked by Wall St. Rank hold DGX as of Q3 2025.

  • Stanley-Laman Group reported no remaining Quest Diagnostics position as of Q3 2025 after selling out during the quarter.
  • Stanley-Laman Group sold 1,398 Quest Diagnostics shares in Q3 2025, an estimated $251K.
  • Stanley-Laman Group first reported a position in Quest Diagnostics in Q1 2025 and held it in 2 quarters.
  • Stanley-Laman Group's Quest Diagnostics position peaked at $251K in Q2 2025.
  • 1,005 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2025.

Based on Stanley-Laman Group's 13F filing for Q3 2025, filed 22 Oct 2025.